

# | 2021-2022 ANNUAL REPORT









## **TABLE OF CONTENTS**

President & Chair's	4
Message Board and Staff	5
Engagement	6
Enrichment	7
Advocacy	9
Membership	11
Financial Statements	14

# Accelerate

ON BEHALF OF THE BOARD AND STAFF,  
WE ARE PLEASED TO PRESENT THE  
BIOALBERTA ANNUAL REPORT AND  
FINANCIAL STATEMENTS FOR THE  
FISCAL YEAR ENDING MARCH 31, 2022.

The past year was an important moment for life sciences in Alberta. Our sector showed its resiliency and commitment to being part of the modern Alberta economy. Our actions as an association focused on providing opportunities for Albertans to learn about life sciences, collaborate with others, and engage with investors, funders and stakeholders.

From education sessions with the Metabolics Innovation Centre (TMIC) to Biotechgate Digital Partner sessions to the Medtech Virtual conference and platform for medical device and health tech companies, we focused on connecting Alberta SMEs with the world. In April, we partnered with Alberta Advanced Education on the Work Integrated Learning Innovation Voucher to provide WIL opportunities to support not only students looking for experiential learning opportunities but our emerging life sciences SMEs. Between Boosting Biotech and WIL, we have placed over 100 students with Alberta companies.

In June, we returned to BIO...Digital!. Our Alberta Life Sciences Showcase virtual event provided presentations from eight of Alberta's most innovative companies that connected our sector to global connections.

2021 saw the release of the State of the Industry Report by Deloitte, the most comprehensive report on Alberta's life sector. The report shows that Alberta's life sciences industry is experiencing incredible growth and opportunities. R&D spending increased since 2018/19, eclipsing \$240 million for the first time since 2017. Companies recorded a record in revenue projects, with the industry expected to see over \$1.3 billion in revenue in 2021. 2020 also saw a record for

financing, with over \$1.5 billion in capital raised, attributed to significant investment in the cannabis sector, as well as strong capital funding allocated for healthcare technology and services in the wake of COVID-19.

In 2021 we also extended our support to the plant protein sector. We are excited to support Alberta's future in value-added processing and alternative proteins. Collaboration, building a larger voice, and investment attraction are pillars of the work underway.

Our most significant impact in the past year was the return of in-person events! In February, we brought back the Prairie Bioeconomy Guild, a monthly networking event for the bioeconomy. We look forward to re-invigorating this important venue for business, research and policymakers to come together.

We were excited to combine our second annual Policy Forum with our 2021 Awards dinner to create the first in-person event for life sciences in two years. Under the theme Partnering for Health Innovation, we discussed how the industry drives health innovation by working in partnership with the government and the health system. Most importantly, our Awards Gala celebrated Alberta's life sciences by recognizing Providence Therapeutics as Company of the Year, and Dr. Ratmir Derda of 48-hour Discovery with Scientific Achievement of the Year. Finally, we were honoured to induct Dr. Michael Houghton into the BioIndustry Hall of Fame and recognize his lifelong achievements.

Looking forward, you can't help but feel the energy and enthusiasm of Alberta's life sciences sector. We are proud to continue to foster and grow Alberta's life sciences network, and be the voice and champion for our sector. But most of all, we are proud to be associated with such innovative people and companies. We look forward to continuing to support you, and celebrating your success as we modernize Alberta's economy!



**Robb Stoddard**  
President & CEO,  
BioAlberta



**Greg Klak**  
Co-Chair,  
BioAlberta



**Nuzhat Tam-Zaman**  
Co-Chair,  
BioAlberta

# BOARD AND STAFF

## BOARD OF DIRECTORS

**Nuzhat Tam-Zaman**, *(Co-chair)* Partner,  
Co-Founder, VP International &  
Regulatory Affairs, SinoVeda Canada Inc.

**Greg Klak**, *(Treasurer)* General Manager,  
Gilead Alberta ULC

**Jason Ding**, *(Chair, Nomination Committee)*  
Chief Business Officer, Entos Pharmaceuticals

**Bridgette Duniece**, VP External Affairs and  
Operations, Permolex Ltd.

**Brent Korte**, Korte Consulting

**Sameeh Salama**, VP Business  
Development, Fedora  
Pharmaceuticals Inc.

**George Samoil**, Retired Executive

**Svetlana Sapelnikova**, KMT Hepatech, Inc.

**Jaspreet Grewal**, Venn Consulting Inc.

**Keith Driver**, Propel Ventures Inc.

**Sandi Wright**, Founder and CEO, Andau Medical  
Inc.

**Sasha Musij**, Growth Solutions Director, Export  
Development Canada

**Darryl Lesiuk**, SmileSonica

**Daria Horbay**, Sr. Manager, Access and  
Government Relations, Pfizer Canada

## COMMITTEES

### Advocacy and Policy Committee

**Brent Korte** (Chair)

**George Samoil**

**Bridgette Duniece**

**Svetlana Sapelnikova**

**Jaspreet Grewal**

**Darryl Lesiuk**

**Sandi Wright**

**Sasha Musij**

**Daria Horbay**

**Ex Officio** : Nuzhat, Greg, Robb

### External Advocacy & Policy Committee

**Laura Fitzgerald** (GSK)

**Rob Lee** (Vertex Pharma)

**Lynda Ravlich** (Abbvie)

**Lorne Koscelniuk** (Servier)

**Jessica Rudd** (Medtronic)

**Mel Wong**

### Finance and Audit Committee

**Keith Driver** (Chair)

**Jason Ding**

**Jaspreet Grewal**

**George Samoil**

**Svetlana Sapelnikova**

**Ex Officio** : Nuzhat, Greg, Robb

### Nominations Committee

**Jason Ding** (Chair)

**Sameeh Salama**

**Darryl Lesiuk**

**Svetlana Sapelnikova**

**Ex Officio** : Nuzhat, Greg, Robb

### Awards & Recognition Committee

**Keith Gilchrist** (Chair)

**Sameeh Salama**

**Sasha Musij**

**Mel Wong**

**Sandi Wright**

**Ryan Heit**

**Ex Officio** : Nuzhat, Greg, Robb

## STAFF

**Robb Stoddard**, *President & CEO*

**Nisarg Patel**, *Manager, Industry  
Development*

**Christy Fehr**, *Office Manager*

**Jamie Anderson- Reid**, *Project  
Coordinator*

**Amrit Kang**, *Manager, Marketing*

# ENGAGE

ACTIVELY ENGAGING MEMBERS WAS A PRIORITY THROUGHOUT THE CHALLENGING 2021-2022 BUSINESS CYCLE. USING VIRTUAL COMMUNICATION PLATFORMS TO GATHER, SHARE AND COLLABORATE SPURRED NEW NETWORKING POSSIBILITIES ACROSS INDUSTRY, AND OPENED UNEXPECTED OPPORTUNITIES TO WORK ACROSS SECTORS AND CONTINENTS.

## Natural Health Products

BioAlberta held its second virtual annual general meeting in its 22-year history on October 15th, 2021.

Following the formal portion of the program, BioAlberta members and the public were able to watch a special keynote presentation by, Jason Ding, Deloitte Corporate Finance Partner & Senior Managing Director who was on screen. Mr. Ding delivered his presentation: a Snapshot of the Life Sciences Industry in Alberta. His informative presentation focused on trends such as the higher proportion of new companies founded in Alberta emerging over the past 3-4 years, forecasted revenues, and COVID-19 impacts among other topics.

## AHS Health Innovation Partnership Platform - ORIENT

BioAlberta held roundtable discussions with health tech SMEs and AHS. The objective of this session was:

- To understand entrepreneurs' lived experiences with learning about the health care system and how that impacted their product's development
- To explore how the ORIENT service can be delivered to meet the entrepreneurs' needs

Overall, the discussion aimed to gather the maximum amount of information from meeting participants to guide the development of the ORIENT service.

## Annual General Meeting

To drive international market development forward, BioAlberta held a special series of in-depth roundtable conversations and examined several potential initiatives that could support Alberta's Natural Health Product companies in their plant protein innovations, and discuss the merits of:

- A collective brand(e.g. an Alberta/Canada brand) for Alberta natural health products
- A collective fulfillment platform to support international sales.
- In these discussions, we worked on a one-on-one basis to introduce them to Trade Commissioner Services and distribution channels in the international markets of their interest.



**Deloitte, Jason Ding, Partner & Senior Managing Director**



# ENRICH

NEW KNOWLEDGE DRIVES ADAPTATION AND TO CREATE FLEXIBLE, HEALTHY AND SUCCESSFUL WORK ENVIRONMENTS. SECTOR GROWTH IS ACHIEVED THROUGH THE EXCHANGE OF IDEAS, LEARNING AND CONVERSATIONS. IN THE NEW BUSINESS WORKPLACE, THE USE OF TECHNOLOGY TO SHARE AND EDUCATE FOSTERED ALLIANCES AND PARTNERSHIPS ON NEW VENTURES.

## BioDigital

**BioAlberta secured a pavilion at BioDigital 2021, where we got to host live pitches and virtual networking showcasing the best of what Alberta companies have to offer.**

The objective was to market and showcase Alberta's biotech industry strengths, and coordinate partner opportunities for BIO delegates interested in Alberta companies.

Attendees heard pitches from leading companies and individuals:

- Li Ka Shing Institute of Virology
- Dr. Lorne Tyrell and Dr. Michael Houghton
- Pacylex Pharmaceuticals Inc.
- Entos Pharmaceuticals
- Resverlogix
- AazeinTx
- 48Hour Discovery
- Providence Therapeutics Inc.
- Northern RNA

We also hosted a networking reception that attracted BioDigital delegates as well as interested participants from across North America and showcased Alberta's capacity related to vaccine development and biomanufacturing.

The Keynote address was delivered by Hon. Doug Schweitzer, Minister of Jobs, Economy and Innovation.



# Prairie Bioeconomy Guild

We saw the return of our Monthly Prairie Bioeconomy Guild. A networking place for passionate professionals in the bioeconomy sector to socialize.

We've hosted over four sessions and heard presentations from numerous influential members of the Life Sciences Industry. Some speakers include:

- Perry Toms, from Steeper Energy, spoke on, how Hydrofaction® is moving quickly towards commercial acceptance.
- Dr. John Yao, from Hermay Labs Corporation, spoke about his vision of Edmonton becoming Canada's next BioHub and the many entrepreneurial opportunities available here!
- Ana Clementin, Executive Director PanTHERA CryoSolutions Inc., who spoke on
- Cryo Preservation and its applications in the Bio-Economy!



**PanTHERA CryoSolutions Inc., Ana Clementin, Executive Director**



**Hermay Labs Corporation, Dr. Yao, President**



# ADVOCATE

THROUGH TARGETED CORRESPONDENCE AND CONVERSATIONS, MEETINGS AND WEBINARS, THE IMPORTANT WORK ACCOMPLISHED BY OUR MEMBERS IS SHARED WITH KEY STAKEHOLDERS, INCLUDING REGULATORS AND LEGISLATORS. WE CONTINUE TO STEER STRATEGIC DIRECTION SO THAT LIFE SCIENCE INDUSTRY EFFORTS, SECTOR BY SECTOR, ARE KNOWN AND UNDERSTOOD BY DECISION-MAKERS AND INFLUENCERS AT LOCAL, PROVINCIAL AND NATIONAL LEVELS.

## BioAlberta Policy Forum and Gala

BioAlberta's Inaugural Policy Forum brought 200 stakeholders and industry leaders across multiple sectors together for a day of panel discussions to discuss “Partnering for Health Innovation”. These crucial discussions and the information gathered help to inform our advocacy efforts planned across the sector throughout the year.

Speakers presented opportunities and critical success factors to demonstrate that partnerships were key in driving innovation into Alberta's health system.

Topics included what Does Partnering for Innovation Mean for Alberta's Health System, Adopting Modern Therapies in Alberta's Health System, Has COVID Changed Canada's Regulatory Environment

The evening featured a Gala dinner, with remarks from Health Minister Jason Copping and a Keynote address from Linda Rootkin, Region Head at Novartis. Following dinner we presented the 2021 BioAlberta Achievement Award Winners. Providence Therapeutics received the Company of the Year, while Dr. Ratmir Derda was honored with the Scientific Achievement and Innovation award.

The night concluded by Inducting Dr. Michael Houghton into the BioIndustry Hall of Fame. Dr. Michael Houghton honored us with his presence via Teams videoconference while his longtime friend and colleague Dr. Lorne Tyrrell accepted the award on his behalf.

*Continued...*

# ADVOCATE



**Policy Forum, "Has COVID changed Canada's Regulatory Environment"**



**Networking Reception**



**Dr. Michael Houghton, Accepting his reward**



**Dr. Ratmir Derda, Accepting "Scientific Achievement and Innovation"**



**BioAlberta Team**



# MEMBERSHIP

## PLATINUM

Deloitte LLP  
GlaxoSmithKline Inc.  
Janssen Inc.  
Merck Canada Inc.  
Novartis Inc.  
Pfizer Canada Inc.

## GOLD

AbbVie Inc.  
AstraZeneca Canada Inc.  
BioTalent Canada  
Boehringer Ingelheim Ltd.  
DynaLife Medical Labs  
Gilead Alberta UIC  
Innovate Calgary  
Innovative Medicines Canada  
Novo Nordisk Canada Inc.  
Hoffman-La Roche Ltd.  
Sanofi Genzyme Canada

## SILVER

AMGEN Canada Inc.  
Bausch Health  
Biogen Inc.  
Edmonton Health City  
Horizon Therapeutics plc  
Kite Pharma, a Gilead Company  
McCarthy Tétrault LLP  
Medtronic Canada ULC  
Servier Canada Inc.  
Takeda Canada Inc.  
TEC Edmonton  
Telus Health  
University of Alberta, Faculty of Medicine and Dentistry  
Vertex

## MEMBERSHIP

48Hour Discovery Inc.  
AbbVie Corporation  
Accumol Inc.  
Agriview Inc.  
Ag-West Bio Inc.  
AirTerra Inc.  
Alberta Health Services  
Alberta Hemp Works  
Alberta Jobs Economy and Innovation  
Alberta Research Chemicals Inc.  
Alberta Rhodiola Rosea Growers  
Alexion  
Organization (ARRGO)  
Allergan Inc.  
Allos Bioscience Ltd.  
ALR Technologies Inc.  
  
Altitude IP  
Amgen Canada Inc.  
Andau Medical  
Astellas Pharma Canada, Inc.  
AstraZeneca Canada Inc.  
ATCO Gas  
  
Aurinia Pharmaceuticals Inc. (AUPH)  
Bast Fibre Technologies Inc.  
Basu, Paramita  
Bausch Health  
Berkley Canada  
Bertech Pharma Ltd.  
BFL Canada Inc.  
BioAtlantech  
Bio-Conversion Databank Foundation  
Bio-Fuels Inc.  
Biogen Inc.  
BioNeutra North America Inc.  
BioNova  
BIOQuebec  
BioRefinex Canada Inc.  
BioTalent Canada  
BIOTECCanada  
Blue Sky Analytical Labs Ltd.  
Bodycad  
Boehringer Ingelheim (Canada) Ltd.  
Borden Ladner Gervais LLP, McLellan Lloyd  
Botaneco Inc.  
BT Neuro-MedWare  
Canadian Bio-Systems Inc.

Canadian Strategy Group  
Canadian Wood Waste & Recycling  
Business  
Group  
Carlisle Consulting Inc.  
CEAPRO Inc.  
Celgene Inc.  
Chenomx Inc.  
Clinisys EMR Inc.  
CNA Diagnostics Inc.  
Creative Protein Solutions  
Criticare Dx  
CSL Behring  
Cytiva  
Dalynn Biologicals Inc.  
Deep Surface Ai Inc.  
Deloitte LLP  
Dentons Canada LLP  
Discovery DNA Inc.  
DynaLIFE Medical Labs  
Easy SR&ED Consultants  
EC Labs  
Edmonton Economic Development Corporation  
Edmonton Health City  
Edmonton International Airport (EIA)  
Eli Lilly Canada Inc.  
Epsilon Chemicals Ltd.  
Expander Energy Inc.  
  
Faba Canada Ltd.  
Fedora Pharmaceuticals Inc.  
Fluid Biotech Inc.  
FluroTech Ltd.  
FREDsense Technologies Corp.  
Future Fields Cellular Agriculture  
Genome Alberta  
Gilead Alberta ULC  
Gilead Sciences Canada Inc.  
GlaxoSmithKline Inc.  
Global Public Affairs  
GrainFrac Inc.  
Habit Creations Inc.  
Hannibal Ventures Inc.  
Hermay Labs Corporation  
Hicks & Associates Intellectual Property  
Hoffmann-La Roche Limited  
Horizon Therapeutics Canada  
Ian Murray & Company  
ICCR (Institute of Continuing Care Education & Research  
Illucidx Inc.



IMBiotechnologies Ltd.  
 Incyte Corporation  
 Innovate Calgary  
 Innovative Medicines Canada  
 Innovative Reduction Strategies Inc. (IRSI)  
 Institute for Continuing Care Education & Research  
 Institute of Health Economics  
 Janssen Inc.  
 Kevin Keough Consulting Inc.  
 Kingsgate Legal  
 KMT Hepatech Inc. / Phoenix Bio Group  
 Korte Consulting  
 Labs-Mart Inc.  
 Li Ka Shing Institute of Virology - University of Alberta  
 Lloyd Sadd Insurance Brokers Ltd.  
 Lochend Luing Ranch  
 Lowen's Natural Skincare  
 Lumiio Health - Previously Datafinity Health Inc.  
 M Consulting Group  
 MACH32  
 MagnetTx Oncology Solutions  
 Medlior Health Outcomes Research Ltd  
 Medtronic of Canada, Inc.  
 Merck Canada Inc.  
 Metabolomic Technologies Inc.  
 MindLab Interactive AI Inc.  
 MLT Aikins LLP  
 Mountain Integrated Medical Devices Inc. (MIMD)  
 More Than Protein Ingredients Ltd.  
 My Viva Inc.  
 MYND Life Sciences  
 Naiad Lab Inc.  
 NanoCanada  
 Nanostics Inc.  
 NanoTess Inc.  
 Natural Products Canada  
 Neogen Canada Inc.  
 Northern Resources Logistics Inc.  
 Northern RNA  
 Northernmost Medical Devices Inc.  
 Novartis Pharmaceuticals Canada Inc.  
 Novo Nordisk Canada Inc.  
 OKR Financial  
 Oncolytics Biotech Inc.

Outbreaker Solutions  
 Pacylex Pharmaceuticals Inc.  
 PanTHERA CryoSolutions  
 Path Therapeutics Inc.  
 PBG BioPharma Inc.  
 Permolex Ltd.  
 Pfizer Canada Inc.  
 PharmaDirections, Inc.  
 Planet Biotechnologies Inc.  
 Plant Protein Alliance of Alberta  
 Propel Ventures  
 PTC Consulting Inc.  
 Qualisure Diagnostics Inc.  
 Rane Pharmaceuticals Inc  
 Resverlogix Corp.  
 RJH Biosciences  
 Salu Design Group Inc.  
 Samoil, George (Consultant)  
 Sanofi Canada  
 SciencePak  
 Servier Canada Inc.  
 Shine Stone International Ltd.  
 SinoVeda Canada Inc.  
 SmileSonica Inc.  
 Sparrow Acoustics  
 Sustrik Law LLP  
 Symbiotic EnviroTek Inc.  
 Takeda Canada Inc.  
 TC Scientific Inc.  
 Technology North Corporation  
 Tevosol Inc.  
 Think Tank Innovations  
 Tipp Consulting  
 Torys LLP  
 TRIO (Translational Research in Oncology)  
 TSGI Corporation  
 University Hospital Foundation  
 University of Alberta – Alberta School of Business  
 University of Alberta – Faculty of Medicine and Dentistry  
 University of Alberta – Faculty of Pharmacy and Pharmaceutical Sciences  
 University of Calgary – Biomedical Engineering

University of Lethbridge  
 Valhalla Private Capital  
 VaxAlta Inc.  
 Venn Consulting Inc.  
 Virtual CFO Solutions  
 VWR International Ltd.  
 Western Economic Diversification  
 Canada What Matters! Consulting  
 XORTX Therapeutics Inc.  
 3M

## INDIVIDUAL

Bricker, Ross  
 Fritzler, Marvin  
 Froelich, Art  
 Graham, Delwin  
 Keough, Kevin  
 Kipp, Michael  
 Leung, Kar  
 McLellan, Lloyd  
 Otieno, Charles  
 Schab, Jennifer  
 Shan, Jacqueline  
 Sustrik, Gordon  
 Tertzakian,  
 Gerard Tyrell,  
 Lorne  
 Wang, Joyce



**ALBERTA BIOTECHNOLOGY ASSOCIATION**  
***(OPERATING AS BIOALBERTA)***  
**FINANCIAL STATEMENTS**  
**YEAR ENDED MARCH 31, 2022**





**ALBERTA BIOTECHNOLOGY ASSOCIATION  
(OPERATING AS BIOALBERTA)  
INDEX TO FINANCIAL STATEMENTS  
YEAR ENDED MARCH 31, 2022**

---

	Page
INDEPENDENT AUDITOR'S REPORT	1 - 2
FINANCIAL STATEMENTS	
Statement of Financial Position	3
Statement of Changes in Net Assets	4
Statement of Revenues and Expenses	5
Statement of Cash Flows	6
Notes to Financial Statements	7 - 10





## ST. ARNAUD PINSENT STEMAN

CHARTERED PROFESSIONAL ACCOUNTANTS

Daniel J. St. Arnaud, CPA, CA\*\*

John H.C. Pinsent, FCPA, FCA, ICD.D\*\*

Benardus C. Steman, CPA, CA, CFA\*\*

### INDEPENDENT AUDITOR'S REPORT

To the Members of Alberta Biotechnology Association (operating as BioAlberta)

#### *Opinion*

We have audited the financial statements of Alberta Biotechnology Association (the "Association"), which comprise the statement of financial position as at March 31, 2022, and the statements of changes in net assets, revenues and expenses and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Association as at March 31, 2022, and the results of its operations and cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations (ASNPO).

#### *Basis for Opinion*

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Association in accordance with ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Responsibilities of Management and Those Charged with Governance for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with ASNPO, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Association's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Association or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Association's financial reporting process.

(continues)

*Auditor's Responsibilities for the Audit of the Financial Statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Association's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Association's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Association to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*John H.C. Pinsent Professional Corporation*

Edmonton, Alberta  
September 22, 2022

John H.C. Pinsent Professional Corporation  
Chartered Professional Accountant



**ALBERTA BIOTECHNOLOGY ASSOCIATION  
(OPERATING AS BIOALBERTA)  
STATEMENT OF FINANCIAL POSITION  
MARCH 31, 2022**

	2022 \$	2021 \$
<b>ASSETS</b>		
<b>CURRENT</b>		
Cash and cash equivalents	2,119,127	2,197,584
Investment in GIC (Note 5)	250,000	254,500
Accounts receivable	96,742	50,313
Prepaid expenses	13,335	11,198
	<u>2,479,204</u>	<u>2,513,595</u>
<b>LIABILITIES</b>		
<b>CURRENT</b>		
Accounts payable and accrued liabilities	72,885	13,912
Deferred sponsorship, membership fees and grants (Note 4)	1,555,339	1,564,349
	<u>1,628,224</u>	<u>1,578,261</u>
CANADA EMERGENCY BUSINESS ACCOUNT LOAN (Note 10)	30,000	30,000
	<u>1,658,224</u>	<u>1,608,261</u>
CONTINGENT LIABILITY (Note 9)		
<b>NET ASSETS</b>		
Unrestricted net assets	455,980	540,334
Internally restricted net assets (Note 7)	365,000	365,000
	<u>820,980</u>	<u>905,334</u>
	<u>2,479,204</u>	<u>2,513,595</u>

**ON BEHALF OF THE BOARD**

\_\_\_\_\_  
Director

\_\_\_\_\_  
Director

*The accompanying notes form part of these financial statements*



**ALBERTA BIOTECHNOLOGY ASSOCIATION  
(OPERATING AS BIOALBERTA)  
STATEMENT OF CHANGES IN NET ASSETS  
YEAR ENDED MARCH 31, 2022**

	Unrestricted net assets \$	Internally restricted net assets \$	<b>2022</b> \$	2021 \$
<b>NET ASSETS - BEGINNING OF YEAR</b>	540,334	365,000	<b>905,334</b>	697,849
EXCESS (DEFICIENCY) OF REVENUES OVER EXPENSES	(84,354)	-	<b>(84,354)</b>	207,485
<b>NET ASSETS - END OF YEAR</b>	455,980	365,000	<b>820,980</b>	905,334

*The accompanying notes form part of these financial statements*



**ALBERTA BIOTECHNOLOGY ASSOCIATION  
(OPERATING AS BIOALBERTA)  
STATEMENT OF REVENUES AND EXPENSES  
YEAR ENDED MARCH 31, 2022**

	2022 \$	2021 \$
<b>REVENUES</b>		
Government grants (Note 8)	297,500	388,267
Partnership program fees	265,063	346,604
Program fees	248,676	435,996
Membership fees	73,093	79,369
Interest income	20,191	10,957
Canada Emergency Business Account loan (Note 10)	-	10,000
	<b>904,523</b>	<b>1,271,193</b>
<b>EXPENSES</b>		
Wages and benefits	485,703	302,280
Program fee costs	294,490	449,202
Consulting fees	82,079	163,591
Rent	48,000	49,889
Information technology and networking	28,519	36,191
Professional fees	11,503	21,949
Office	8,852	13,279
Telephone	7,815	7,267
Travel	7,245	1,497
Advertising and promotion	5,380	10,960
Insurance	4,561	3,937
Interest and bank charges	3,212	3,666
Training	1,518	-
	<b>988,877</b>	<b>1,063,708</b>
<b>EXCESS (DEFICIENCY) OF REVENUES OVER EXPENSES</b>	<b>(84,354)</b>	<b>207,485</b>

The accompanying notes form part of these financial statements



**ALBERTA BIOTECHNOLOGY ASSOCIATION  
(OPERATING AS BIOALBERTA)  
STATEMENT OF CASH FLOWS  
YEAR ENDED MARCH 31, 2022**

	2022 \$	2021 \$
<b>OPERATING ACTIVITIES</b>		
Excess (deficiency) of revenues over expenses	<u>(84,354)</u>	207,485
Changes in non-cash working capital:		
Accounts receivable	(46,429)	10,713
Accounts payable and accrued liabilities	58,973	(18,098)
Deferred sponsorship, membership fees and grants	(9,010)	338,139
Prepaid expenses	<u>(2,137)</u>	2,998
	<u>1,397</u>	333,752
Cash flow from (used by) operating activities	<u>(82,957)</u>	541,237
<b>INVESTING ACTIVITIES</b>		
Redemption of GIC	254,500	250,000
Investment into GIC	<u>(250,000)</u>	(254,500)
Cash flow from (used by) investing activities	<u>4,500</u>	(4,500)
<b>FINANCING ACTIVITY</b>		
Canada Emergency Business Account Loan	<u>-</u>	30,000
<b>INCREASE (DECREASE) IN CASH FLOW</b>	<b>(78,457)</b>	566,737
Cash - beginning of year	<u>2,197,584</u>	1,630,847
<b>CASH - END OF YEAR</b>	<u><b>2,119,127</b></u>	<u>2,197,584</u>

*The accompanying notes form part of these financial statements*





**ALBERTA BIOTECHNOLOGY ASSOCIATION  
(OPERATING AS BIOALBERTA)  
NOTES TO FINANCIAL STATEMENTS  
YEAR ENDED MARCH 31, 2022**

---

**1. PURPOSE OF THE ORGANIZATION**

The Alberta Biotechnology Association (the "Association") is a not-for-profit organization incorporated under the Societies Act of Alberta on October 15, 1998. The Association was formed to provide leadership towards the creation of a strong, viable biotechnology industry in Alberta by promoting the growth of biotechnology businesses and firms and providing an authoritative voice within Alberta, nationally and internationally on industry issues. The Association is not subject to income tax.

**2. SIGNIFICANT ACCOUNTING POLICIES**

Basis of presentation

The financial statements were prepared in accordance with Canadian accounting standards for not-for-profit organizations ("ASNFPO"). The financial statements have, in management's opinion, been properly prepared within the reasonable limits of materiality and within the framework of the accounting policies summarized below.

Cash and cash equivalents

The Association considers all bank accounts, liquid investments with maturities of three months or less and bank loans with no fixed terms of repayment to be cash and cash equivalents. All amounts held for investment purposes are valued at the lower of cost and fair market value.

Revenue recognition

The Association follows the deferral method of accounting for contributions.

Restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Program fees are recognized in the period in which the related program is conducted. Program fees received in advance of the program are deferred.

Membership and partnership fees are recognized over the membership and partnership term. Membership and partnership fees related to terms extending past the year-end are deferred.

Government grants are recognized in the period in which the related program is conducted. Government grants received in advance are deferred.

Contributed services

The Association receives volunteer assistance from its members and sponsor organizations. Contributed services and donated goods are not recognized in the financial statements, as the fair value cannot be reasonably estimated.

Measurement uncertainty

The preparation of financial statements in conformity with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Such estimates are periodically reviewed and any adjustments necessary are reported in earnings in the period in which they become known. Actual results could differ from these estimates.



**ALBERTA BIOTECHNOLOGY ASSOCIATION**  
**(OPERATING AS BIOALBERTA)**  
**NOTES TO FINANCIAL STATEMENTS**  
**YEAR ENDED MARCH 31, 2022**

---

**3. FINANCIAL INSTRUMENTS**

The Association initially measures its financial assets and financial liabilities at cost. The Association subsequently measures all its financial assets and financial liabilities at amortized cost except for investments in GICs, which it chooses to measure at fair value. Changes in fair value are recognized in the statement of revenue and expenses.

Credit risk

Credit risk arises from the potential that a counter party will fail to perform its obligations. Financial instruments that subject the Association to credit risk consist primarily of cash and cash equivalents and accounts receivable. The Association provides services to a diverse membership base and its credit risk is not concentrated in any one particular member or group.

Interest rate risk

Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. In seeking to minimize the risks from interest rate fluctuations, the Association manages exposure through its normal operating and financing activities. The Association is exposed to interest rate risk arising from fluctuations in interest rates on cash and cash equivalents held by financial institutions.

**4. DEFERRED SPONSORSHIP, MEMBERSHIP FEES, AND GRANTS**

The Association bills its members an annual fee at the date of the members' renewal. A total of \$31,855.83 (2021 - \$24,303) of membership fees were deferred at the end of March 31, 2022, representing prepayment of membership fees for the fiscal 2023 year.

The Association also receives revenue from corporate partnerships. A total of \$257,250 (2021 - \$76,313) was deferred as of year end.

During the fiscal year, the Association received project funding from various government agencies. As at March 31, 2022, \$1,266,233 (2021 - \$1,463,733) in grant funding was deferred.

Due to complications arising from the COVID-19 pandemic, there is some uncertainty as to whether the Association will be able to fulfill the obligations from one government grant within the initially proposed timeline. The funds will remain in deferred revenue until the Government has a clear plan on how it wants the Association to treat the remaining funds.

As at March 31, 2022, a total of \$1,555,339 (2021 - \$1,564,348) had been deferred.

**5. INVESTMENT IN GIC**

The Association invested into a GIC on August 26, 2021. The principal amount invested was \$250,000, and the GIC pays interest at 0.45%. The maturity date is August 26, 2022.



**ALBERTA BIOTECHNOLOGY ASSOCIATION  
(OPERATING AS BIOALBERTA)  
NOTES TO FINANCIAL STATEMENTS  
YEAR ENDED MARCH 31, 2022**

**6. COMMITMENTS**

The Association has entered into an agreement to pay monthly property lease costs, with an initial term of five years and one month, commencing on the first day of July 2018.

Aggregate base payments required under all operating leases over the next two years are as follows:

	\$
2023	20,232
2024	6,744
	<u>26,976</u>

**7. INTERNALLY RESTRICTED NET ASSETS**

The purpose of the internally restricted fund is to sustain basic operations and core member services during a short-term economic downturn or a temporary lapse in funding, to provide for wind-down costs in the event of funding withdrawal, to provide a source of funds, over and above potential insurance reimbursement, or for capital asset replacement in the event of disaster. The fund was established in 2005 for \$325,000 with an additional \$75,000 transferred to the fund in fiscal 2006, \$100,000 in fiscal 2009, and \$100,000 in fiscal 2011. In 2016, the Board of Directors approved a \$235,000 transfer from internally restricted to unrestricted net assets. The fund balance as at March 31, 2021 was \$365,000 (2020 - \$365,000).

**8. GOVERNMENT GRANTS**

The Association has recognized funding under the following government grants:

	2022 \$	2021 \$
Alberta Economic Development and Trade	145,000	388,267
Alberta Advanced Education - Work Integrated Learning	146,500	-
Government of Alberta - Labour Market Intelligence study	6,000	-
	<u>297,500</u>	388,267

On March 19, 2019, the Association received grant funding for up to \$1,240,000 from Alberta Economic Development and Trade to fund multi-year projects to address talent development, and to support medical device and natural health product development for Alberta companies.

On March 19, 2021, the Association received grant funding for up to \$782,000 from Alberta Advanced Education and Trade in the form of a Work Integrated Learning ("WIL") grant to fund multi-year projects to address talent development, and to support valuable mentorship and internship opportunities for Alberta students.

On February 20, 2022, the Association received grant funding for \$100,000 from the Government of Alberta for a Labour Market Intelligence ("LMI") study specifically tailored to the life sciences industry in Alberta.

The funds from grants are restricted to the project deliverables as defined in the respective grant agreements.



**ALBERTA BIOTECHNOLOGY ASSOCIATION**  
**(OPERATING AS BIOALBERTA)**  
**NOTES TO FINANCIAL STATEMENTS**  
**YEAR ENDED MARCH 31, 2022**

---

**9. CONTINGENT LIABILITIES**

There is some uncertainty in the amount of the Alberta Economic Development and Trade grant that covers the period up until July 31, 2022. BioAlberta has submitted documentation to Alberta Economic Development and Trade and is waiting for a decision. The amount presented in the financial statements as deferred revenue is an estimate based on information known at the time the financial statements were prepared.

**10. COVID-19**

On March 17, 2020, the Government of Alberta declared a public health emergency in response to the COVID-19 global pandemic. The financial impact of this public health emergency had rapidly evolving, which precludes a reasonable estimate of the overall impact on the Association.

The Association applied for and received the Canada Emergency Business Account loan for \$40,000 of which \$10,000 of this loan is forgivable and has been recognized as income in the prior year.





